Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Stephan Märsch

Hans-Georg Lerchen

Beatrix Stelte-Ludwig

Anne-Sophie Rebstock

Simone Greven

Christoph Mahlert

Dennis Kirchhoff

Yolanda Cancho Grande

Lisa Dietz

Sven Wittrock

Sandra Berndt

Stefanie Hammer

Anette Sommer

Uwe Gritzan

Ernst Weber

Christian Votsmeier

Mark Trautwein

Dorian Schönfeld

Nikolaus Pawlowski

Julian Marius Glück

Patrick Jones

Jenny Fitting

The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.

Antibody drug conjugates (ADCs) having enzymatically cleavable groups

The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies

Antibody drug conjugates (ADCS) having enzymatically cleavable groups

Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.

Specific antibody drug conjugates (ADCs) having KSP inhibitors

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies

The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD 123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies

Growing community of inventors

Cologne, Germany

Stephan Märsch